Previous Close | 7.51 |
Open | 7.57 |
Bid | 0.00 x 900 |
Ask | 0.00 x 800 |
Day's Range | 6.95 - 7.65 |
52 Week Range | 1.69 - 20.75 |
Volume | 84,084 |
Avg. Volume | 108,813 |
Market Cap | 207.567M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.30 |
Earnings Date | Nov 13, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.25 |
25, 2021 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences: * The Cowen 41st Annual Health Care Conference's panel on Cardiovascular Disease and Hospital Products on Thursday, March 4, 2021 at 1:30 p.
If you want to know who really controls Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ), then you'll have to look at the...
In this article we will take a look at whether hedge funds think Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]